Език: EN EN
← Назад към резултатите
Активно (без набиране) NCT06187103

Evaluation of Improved Onboard Patient Imaging

Заболявания: Head and Neck Cancer Breast Cancer Upper Gastrointestinal Cancer Lung Cancer Pelvic Cancer

Спонсор: Varian, a Siemens Healthineers Company

Налично на: БГ
Обобщение
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.
Кой може да участва
Inclusion Criteria: 1. Patient is willing and able to provide written consent. 2. Patient is at least 18 years of age at the time of consent. 3. Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis. 4. Patient has ECOG performance status 0-2. 5. Patient will be receiving radiation therapy at University of Maryland Medical Center, Department of Radiation Oncology. Exclusion Criteria: 1. Patient is pregnant or attempting pregnancy. 2. Patient has known genetic pre-disposition for sensitivity to radiation (e.g., Li Fraumeni). 3. Patient receives palliative radiation for 5 or fewer fractions. 4. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.
Интервенции
HyperSight Imaging
DEVICE
Места на провеждане 1
САЩ (1)
University of Maryland Medical Center
Baltimore , Maryland
Технически детайли
Статус
Активно (без набиране)
Вид изследване
OBSERVATIONAL
Пол
Мъже и жени
Минимална възраст
18 Years
Здрави доброволци
Не
Начална дата
10.07.2024
Крайна дата
01.12.2026
Регистрационен номер
NCT06187103
Източник
clinicaltrials.gov
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.